Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda’s new round values the AI drug-discovery startup at $2 billion, twice where it stood a year ago.
The $311 million Series E was led by Catalio Capital Management, with Iconiq among the participants. Enveda uses AI to search plants and microbes for drug candidates rather than synthesizing them from scratch. It is testing several candidates in patients, including treatments tied to severe skin conditions and maintaining weight loss after GLP-1 use. TechCrunch AI's note
The $311 million Series E was led by Catalio Capital Management, with Iconiq among the participants. Enveda uses AI to search plants and microbes for drug candidates rather than synthesizing them from scratch. It is testing several candidates in patients, including treatments tied to severe skin conditions and maintaining weight loss after GLP-1 use. TechCrunch AI's note
score 8